Gilead Sciences’ Top Line to Remain Muted
Image shown: Gilead holds an impressive share of the US HIV market, both on an infected and diagnosed basis. Source: Gilead Sciences fourth quarter presentation. Simulated newsletter portfolio idea Gilead Sciences continues to battle intensifying competition in the HCV market, which has been able to offset its strength in HIV. Top-line growth has been nothing short of elusive, and management does not expect to return to material growth in the near term. By Kris Rosemann Shares of simulated newsletter portfolio idea Gilead Sciences (GILD) faced a bit of selling pressure following the February 4 release of its fourth quarter results, as it continues to be unable to drive top-line growth. HCV product sales continued to drop precipitously in the period … Read more